Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of dupilumab in moderate to severe asthma after TRAVERSE
NL-OMON45884Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in asthma, sponsored by Sanofi. Primary endpoint: Treatment-emergent adverse events. Started Jun 2019; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON45884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45884.